RetinalGenix amends warrant to bar exercise until 2030 or 3 yrs after uplisting

RetinalGenix Technologies Inc.

Amendment restricts exercise of 28,014,540-share pre-funded warrant held by Sanovas Ophthalmology, LLC.
New exercise limitation: earlier of Feb 1, 2030 or 3rd anniversary of uplisting to Nasdaq or NYSE American.
CEO Jerry Katzman signed for both company and holder (Sanovas Ophthalmology, LLC).
No other terms of the warrant were modified; $100 consideration paid.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.